PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 29 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Active compounds
Mechanism of action
Clinical evidence
Acteoside, a phenylethanoid glycoside found in D. erecta, is a drug in clinical trials for patients with IgA nephropathy [PMID:35405253]
Hydroethanolic extracts of leaves, ripe and unripe fruits demonstrated acute hepatoprotective efficacy against CCl4- and acetaminophen-induced hepatotoxicity in animals [PMID:33505464]
Methanolic extract of leaves showed anti-urolithiatic activity by inhibiting the formation of calcium oxalate and calcium oxalate monohydrate crystals in vitro and in vivo (Wistar rats) [PMID:29636214]
Fruit extracts demonstrated in vitro anthelminthic properties and were tested in vivo using mice infected with Heligmosomoides bakeri [PMID:29414120]
Safety & adverse effects
Evidence summary
PubMed sources
- 1.PMID: 35405253 (2022) — Duranta erecta Linn: A critical review on phytochemistry, traditional uses, pharmacology, and toxicity from phytopharmaceutical perspective. · Journal of ethnopharmacology
- 2.PMID: 28082794 (2016) — An Updated Review on Phytochemical Properties of "Golden Dewdrop" Duranta erecta. · Pharmacognosy reviews
- 3.PMID: 36290660 (2022) — The Antioxidant and Enzyme Inhibitory Potential of n-Hexane-Extracted Oils Obtained from Three Egyptian Cultivars of the Golden Dewdrop Duranta erecta Linn. Supported by Their GC-MS Metabolome Analysis and Docking Studies. · Antioxidants (Basel, Switzerland)
- 4.PMID: 29636214 (2019) — Patho-physiological evaluation of Duranta erecta for the treatment of urolithiasis. · Journal of Ayurveda and integrative medicine
- 5.PMID: 30722635